Event
Wandercraft's Atalante X exoskeleton receives FDA clearance for spinal cord injury rehabilitation
Key points
- • Wandercraft received FDA clearance for its Atalante X exoskeleton to be used in rehabilitation for individuals with spinal cord injuries ...
- • This clearance was supported by safety and effectiveness data from over 500 patients, including clinical trials and real-world evidence.
- • Atalante X is the only FDA-cleared exoskeleton with a powered ankle mechanism that mimics natural human gait.
Company context
Develops self-balancing robotic exoskeletons designed to restore walking ability for people with mobility impairments. The systems use dynamic stabilization to enable hands-free locomotion without crutches or walkers.
Context
- Company
- Wandercraft
- Segment
- Healthcare
- Event type
- Regulatory
- Geography
- Paris · France